Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences



Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits
Against Gilead Sciences

CAMBRIDGE, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals,
Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral diseases, today
announced that it has filed two lawsuits against Gilead Sciences, Inc.
(Nasdaq:GILD): a patent infringement lawsuit in the United States District
Court in Boston, Massachusetts and a separate patent infringement and
interference lawsuit in the United States District Court in Wilmington,
Delaware.

The Massachusetts infringement lawsuit alleges that Gilead infringes two U.S.
patents co-owned by Idenix (6,914,054 and 7,608,597) that cover methods of
treating the hepatitis C virus using 2'-methyl nucleosides. In this lawsuit,
Idenix is seeking a declaration that Gilead's imminent distribution,
importation, use, sale or offer to sell drugs containing sofosbuvir, a
2'-methyl nucleoside compound, infringes Idenix's patents.

The Delaware infringement and interference lawsuit alleges that Gilead
infringes a separate U.S. patent co-owned by Idenix (7,608,600) that covers
methods of treating the hepatitis C virus using 2'-methyl-2'-fluoro
nucleosides. Idenix is seeking a declaration that Gilead's imminent
distribution, importation, use, sale or offer to sell drugs containing
sofosbuvir infringes the Idenix '600 patent. Additionally, the Delaware
lawsuit asserts a claim for interfering patents between the Idenix '600 patent
and a U.S. patent (8,415,322) owned by a Gilead subsidiary, Gilead Pharmasset
LLC. Idenix is seeking to have the Gilead '322 patent declared invalid.

"Idenix has invested significant resources in nucleoside drug discovery and in
building an intellectual property portfolio that aids in the discovery and
development of drugs for the treatment of the hepatitis C virus and other
viral diseases," said Maria Stahl, senior vice president and general counsel
at Idenix. "While we have attempted to resolve this matter with Gilead without
resorting to infringement litigation, we intend to diligently and vigorously
protect our patent rights for the benefit of our company and our shareholders
and prevent infringing use by others. Idenix remains confident in its patent
portfolio and has several patent families that provide the Company coverage
for 2'-methyl nucleoside compounds and 2'- methyl, 2'- fluoro nucleoside
compounds specifically."

Other Ongoing Patent Disputes 

Idenix and Gilead are currently involved in a separate patent interference
before the United States Patent and Trademark Office involving a pending
Idenix patent application (Application 12/131,868) covering certain 2'-
methyl, 2'- fluoro nucleoside compounds and another granted Gilead patent
(7,429,572) also related to certain 2'- methyl, 2'- fluoro nucleoside
compounds. 

Gilead Sciences has also filed suit against Idenix in various jurisdictions
outside the United States to invalidate granted Idenix patents covering
certain 2'-methyl-2'-fluoro nucleoside compounds and their use in treating HCV
or other Flaviviridae viruses. 

The patents asserted by Idenix in its Massachusetts infringement lawsuit are
not the same patents at issue in the ongoing U.S. patent interference or the
ongoing foreign litigations. The patent asserted by Idenix in its Delaware
lawsuit is not the same patent application at issue in the ongoing U.S. patent
interference, but is in the same patent family.

ABOUT IDENIX

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical Company engaged in the discovery and development of drugs
for the treatment of human viral diseases. Idenix's current focus is on the
treatment of patients with hepatitis C infection. For further information
about Idenix, please refer to www.idenix.com.

CONTACT: Idenix Pharmaceuticals Contact:
         Teri Dahlman, Dahlman.Teresa@idenix.com

Idenix Pharmaceuticals logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement